Publication & Citation Trends
Publications
23 total
Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study
Cited by 25
OpenAlex
Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.
Cited by 20
OpenAlex
Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study
Cited by 23
OpenAlex
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience PDF
Cited by 597
OpenAlex
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
Cited by 113
OpenAlex
Research Topics
Lymphoma Diagnosis and Treatment
(12)
Chronic Lymphocytic Leukemia Research
(11)
CAR-T cell therapy research
(5)
Monoclonal and Polyclonal Antibodies Research
(4)
Viral-associated cancers and disorders
(3)
Affiliations
University of Toronto
Leicester Royal Infirmary
Birmingham Children's Hospital
Roche (United Kingdom)
Moredun Research Institute